Engineering Peptide Inhibitors To Overcome PDZ Binding Promiscuity

scientific article published on December 17, 2010

Engineering Peptide Inhibitors To Overcome PDZ Binding Promiscuity is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ANIE.201005575
P953full work available at URLhttps://europepmc.org/articles/pmc3037833?pdf=render
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21105032/pdf/?tool=EBI
https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fanie.201005575
https://doi.org/10.1002/anie.201005575
https://europepmc.org/articles/PMC3037833
https://europepmc.org/articles/PMC3037833?pdf=render
https://onlinelibrary.wiley.com/doi/pdf/10.1002/anie.201005575
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21105032/?tool=EBI
P932PMC publication ID3037833
P698PubMed publication ID21105032
P5875ResearchGate publication ID49633398

P50authorPrisca BoisguerinQ55117843
P2093author name stringRudolf Volkmer
Lars Vouilleme
Dean R. Madden
Patrick R. Cushing
P2860cites workNew insights into cystic fibrosis: molecular switches that regulate CFTRQ56680230
Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domainsQ80459449
The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchangeQ24310009
A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteinsQ24316901
Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activityQ24515074
Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZQ27732927
WebLogo: A Sequence Logo GeneratorQ27860646
EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinomaQ28182609
Recognition of unique carboxyl-terminal motifs by distinct PDZ domainsQ29547580
Small-molecule inhibitors of protein-protein interactions: progressing towards the dreamQ29617758
Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptidesQ30163803
PDZ Domain Proteins: Plug and Play!Q30164767
The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applicationsQ30838479
Characterization of a putative phosphorylation switch: adaptation of SPOT synthesis to analyze PDZ domain regulation mechanismsQ33304541
A specificity map for the PDZ domain familyQ33373127
Synthesis and application of peptide arrays: quo vadis SPOT technologyQ33444964
Design of protein-interaction specificity gives selective bZIP-binding peptides.Q34975999
PDZ domains-glue and guide.Q35169335
PDZ domain binding selectivity is optimized across the mouse proteomeQ40191457
NHE3 inhibits PKA-dependent functional expression of CFTR by NHERF2 PDZ interactions.Q40258288
Ezrin controls the macromolecular complexes formed between an adapter protein Na+/H+ exchanger regulatory factor and the cystic fibrosis transmembrane conductance regulatorQ40380183
The relative binding affinities of PDZ partners for CFTR: a biochemical basis for efficient endocytic recyclingQ41893473
A stabilizing influence: CAL PDZ inhibition extends the half-life of ΔF508-CFTR.Q42031640
Synthesis and screening of support-bound combinatorial peptide libraries with free C-termini: determination of the sequence specificity of PDZ domainsQ46783302
P433issue51
P407language of work or nameEnglishQ1860
P304page(s)9912-9916
P577publication date2010-12-01
2010-12-17
P1433published inAngewandte Chemie International EditionQ62023953
P1476titleEngineering peptide inhibitors to overcome PDZ binding promiscuity
Engineering Peptide Inhibitors To Overcome PDZ Binding Promiscuity
P478volume49

Reverse relations

cites work (P2860)
Q92996885A Multireporter Bacterial 2-Hybrid Assay for the High-Throughput and Dynamic Assay of PDZ Domain-Peptide Interactions
Q45996867A Phosphosite within the SH2 Domain of Lck Regulates Its Activation by CD45.
Q43832133Absolute free energies of biomolecules from unperturbed ensembles
Q34066239Chemically modified peptide scaffolds target the CFTR-associated ligand PDZ domain
Q21145315Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity
Q35468530Computational design of selective peptides to discriminate between similar PDZ domains in an oncogenic pathway
Q34925645Crystallization and preliminary diffraction analysis of the CAL PDZ domain in complex with a selective peptide inhibitor
Q52689243Cysteine modifiers suggest an allosteric inhibitory site on the CAL PDZ domain.
Q41955342Hybrid organic-inorganic inhibitors of a PDZ interaction that regulates the endocytic fate of CFTR.
Q40995571MFPred: Rapid and accurate prediction of protein-peptide recognition multispecificity using self-consistent mean field theory
Q90623692MotifAnalyzer-PDZ: A computational program to investigate the evolution of PDZ-binding target specificity
Q50976881Optimization of the process of inverted peptides (PIPEPLUS) to screen PDZ domain ligands.
Q92102996PDZ Domains as Drug Targets
Q91913292Specificity in PDZ-peptide interaction networks: Computational analysis and review
Q27675510Stereochemical Determinants of C-terminal Specificity in PDZ Peptide-binding Domains: A NOVEL CONTRIBUTION OF THE CARBOXYLATE-BINDING LOOP
Q27680564Stereochemical Preferences Modulate Affinity and Selectivity among Five PDZ Domains that Bind CFTR: Comparative Structural and Sequence Analyses
Q27002520Synthetic peptide arrays for investigating protein interaction domains

Search more.